Ultivue Announces Multiple Events for Multiplex Immunofluorescence and Image Analysis Technology in Immuno-Oncology Research at AACR 2022
Ultivue, Inc. an industry leader in multiplexing tools powered by their emerging novel AI-driven image analysis solutions for tissue biomarker studies, today announced that data from its FlexVUE™ formatting for panel design and its newest mouse panel offering for multiplex immunofluorescence (mIF) and spatially resolved biomarker analysis will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022. The meeting runs from April 8th to April 13th in New Orleans, LA.
April 6, 2022
Accepted abstracts during the AACR conference will feature new data from a streamlined pre-optimized protocol enabling mIF staining on mouse tissue for an improved workflow to investigate T-cell infiltration and additional analysis of the tumor immune microenvironment (TiME) to address the mechanisms of action of immune-related drugs in preclinical syngeneic or GEMM mouse models.
The company will also spotlight an early access program for mouse researchers interested in exploring the use of advanced pre-clinical tools to probe the dynamic nature of events occurring in the TiME. Additional abstracts feature the new flexible mIF assays (FlexVUE™ panels) for discerning relevant distributions of infiltrating immune cells in tumors coupled with UltiStacker® software for producing detailed spatial characterizations of specific cell phenotypes.
Further datasets showcase the integrated capabilities from Fluidigm and Visiopharm to demonstrate a unique tissue phenotyping workflow combining complementary methods that can unravel the complexity of the tumor microenvironment.
Ultivue’s newest workflow to be highlighted at this year’s AACR will be available through the Company’s CLIA services lab and features a multi-omics analysis that demonstrates the versatility of Ultivue’s InSituPlex® technology (ISP) through an integrated workflow for co-detection of protein and RNA on a single tissue section.
Ultivue will also host its 2nd annual Biomarker Insights Summit on April 8th, 2022, ahead of the annual AACR meeting. This symposium is designed to promote thought leadership and has been exclusively curated for those working towards the eradication of cancer via immuno-oncology approaches. Scientists from AstraZeneca, Takeda, Gilead, Merck, Bayer, and many more will be onsite to share successes and lessons learned to better inform therapeutic efforts and explore how innovative digital pathology insights can provide benefit to clinical trials. For more information, visit biomarkerinsightssummit.com.
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at ultivue.com.
Vice President Marketing
October 15, 2021
The Path(ology) Not Taken
As I approach my one-year anniversary with Ultivue, I am excited to be part of a vibrant, rapidly growing company committed to transforming anatomic pathology with our next generation staining technology, InSituPlex®.
Keith Wharton, Jr., MD Ph.D. FCAP
December 16, 2021
TiME for a New Vue of the Tumor Landscape
If you stand too close to the painting for too long observing all the details, you begin to lose sight of what those brush strokes have created. Only when you step back to take in the scene can you have a full understanding and appreciation for how the individual elements come together to create a work of art.
Kirsty Maclean Ph.D.
October 26, 2022
Living in a Spatial World Q&A, Part 2
GEN: Typically, image analysis tools are greatly influenced by inconsistent staining results and even different techniques used for multiplexing. How does the software used by OracleBio account for inter- and intra-run variability in staining quality? Lorcan. To be honest, we do see staining variability in some sample sets, especially in complex tissues from large clinical
Lorcan Sherry Ph.D
December 9, 2022
SITC recap 2022
It was a record year of attendance at this year’s 37th annual SITC meeting. Whether reflective of waning new Covid cases from a peak in late January 2022, a new location, or merely the appetite to meet up with colleagues, check out new technologies or be part of important scientific discussions-Boston SITC had it all.
Kirsty Maclean Ph.D.
September 13, 2021
Every Flavor Has a Story
I have learned in my career that there is a special recipe for making young companies successful. You need to have an amazing product that enables customers to accomplish their goals in a better way than their current method.
October 26, 2022
Living in a Spatial World Q&A, Part 1
GEN: If I were to design my own panel for immunofluorescence, what are the main considerations, given everything you’ve suggested during the webinar for validation? Angela: There are several things one needs to think about when you build a new panel for multiplexed immunofluorescence. You need to consider the abundance of the targets to be
Angela Vasaturo Ph.D.
March 30, 2022
Better Laid Plans of Mice and Men
Adapted from a line in “Ode to a Mouse” from fellow countryman Robert Burns, the phrase, “the best-laid plans of mice and men often go awry”, indicate that no matter how carefully a project is planned, something may still go wrong with it unfortunately speaks to the reality of clinical trials for novel therapeutics, with approximately only 11% of drugs that begin phase I clinical trials eventually being licensed.
Kirsty Maclean, Ph.D.
September 15, 2021
Don’t Knock It TIL You’ve Tried It
I’ve always been curious, with a need to be on the cutting edge of scientific innovation, so after a successful academic career I moved to the rapidly evolving world of biotech. A 15-year journey in this space ultimately led me to Ultivue, their novel InSituPlex® assay, and following advances in tissue multiplexing.
Kirsty Maclean Ph.D.